Methodology 4 min read
Cycling Peptides On and Off: A Plain-English Guide to Why and When
A patient explainer on why most peptide protocols use a cycle pattern rather than continuous use, what the science behind tolerance and receptor regulation says, and how to think about cycle length for your specific protocol goal.
Last reviewed: May 2026
If you have read more than a couple of peptide protocols, you have probably noticed that almost all of them use cycle patterns. Eight weeks on. Ten weeks on. Twelve on, twelve off. The numbers vary but the structure is consistent: protocols are not designed for continuous use. There is always a break.
This guide explains why, in plain English. The short answer: receptors get tired, mechanisms downregulate, and you get less from the same dose over time. The longer answer involves a few different reasons that apply differently to different compounds, and getting the cycle length right matters more for some compounds than for others.
The core idea
Most peptides work by binding receptors on cell surfaces. The receptor reads the binding event and triggers a cellular response. When you run a compound continuously, the cells respond by producing fewer receptors. This is called downregulation. It is one of the body’s mechanisms for keeping signalling systems balanced.
The practical effect: after several weeks of continuous use, the same dose produces a smaller response than it did at the start. The peptide is doing less because the cells have less infrastructure to receive its signal. A break gives the cells time to rebuild receptor density. When you start the next cycle, the response is closer to what it was at the original baseline.
This is the textbook explanation. Real protocols add a few more reasons.
Receptor desensitisation vs receptor downregulation
These are two different things, and they happen on different timescales.
Desensitisation is fast. A receptor that has been activated repeatedly enters a temporarily reduced-response state within hours. This is one reason GH-secretagogue compounds are typically run with at least 90-minute spacing between doses on a given day, not back-to-back administrations.
Downregulation is slower. The cell physically reduces the number of receptors it produces, in response to chronically elevated signalling. This takes weeks. The recovery from downregulation also takes weeks. This is the timescale that cycle patterns address.
The two mechanisms compound. A protocol that produces both fast desensitisation and slow downregulation will see diminishing returns much faster than the half-life of the compound alone would predict.
Why cycle lengths vary by compound class
GH-pulse compounds (CJC-1295, Ipamorelin, sermorelin) show the clearest receptor downregulation. Continuous use beyond 12 weeks tends to produce notably reduced GH response. Standard cycle pattern: 8 to 12 weeks on, equivalent break, repeat. This is one of the better-established cycle conventions.
Recovery peptides (BPC-157, TB-500) show less clear receptor-downregulation behaviour in the published literature. The typical 4-to-12-week cycle pattern for these compounds is more about practical protocol design than about strict receptor regulation. Researchers often run shorter, intensive cycles for acute recovery contexts and longer, lower-dose cycles for chronic-use contexts.
Longevity peptides (NAD+, MOTS-c, Epitalon) have varied cycle conventions. Epitalon famously uses short courses (10 to 20 days) repeated once or twice per year. NAD+ and MOTS-c protocols tend to use longer continuous periods. The cycle conventions here are more about protocol design philosophy than about receptor biology specifically.
GLP-class compounds (codenames SG, MNJ, RT) are the unusual case. The published Phase 3 trial protocols ran continuously for 68 weeks. The cycle conversation for these compounds is different from the peptide-protocol convention generally. Researchers running GLP-class compounds typically use a continuous protocol followed by a maintenance phase, not the on-off cycle pattern that defines other peptide protocols. Our GLP timeline piece covers the response curve.
What happens during the off-cycle
The off-cycle is not just a pause. Three things happen:
First, receptors recover. The cellular machinery that was downregulated during the on-cycle returns toward baseline. This is the mechanistic reason for the break.
Second, the compound clears from circulation. Most peptides have plasma half-lives measured in minutes to hours. Within a day or two of the last dose, plasma levels are negligible. Within a week, tissue levels have followed.
Third, you get a chance to evaluate. This is the operational reason that often matters more in practice than the receptor-biology reason. During an active protocol, every change in your subjective state could be from the protocol or from something else. During an off-cycle, the protocol is no longer a variable. You can see what your baseline is without it. The next decision (run another cycle? change the protocol? stop?) is informed by that comparison.
How to choose your cycle length
The starting framework for first-time researchers:
Recovery protocols: 8 to 12 weeks on, equivalent off. The compound has had time to do measurable work, and the cycle length is short enough to evaluate honestly.
GH-pulse protocols: 8 to 12 weeks on, 8 to 12 weeks off. Receptor downregulation is the binding constraint.
Longevity protocols: more variable. NAD+ and MOTS-c often run 12 to 24 weeks continuous, with shorter breaks. Epitalon-specific protocols run 10 to 20 day courses, twice yearly.
Cognitive protocols (Selank, Semax): typically 2 to 4 weeks of consistent use, then breaks. Tolerance can develop with these compounds, and the cycle pattern is meant to maintain effect.
What not to do during the off-cycle
Two common mistakes:
Stacking new compounds during the off-cycle of an existing one. This defeats the evaluation purpose of the break. If you are off your peptide protocol but starting a new supplement, training programme, or diet pattern, you have not really left the experiment.
Lengthening the off-cycle indefinitely. The break is meant to be a defined window, not an exit ramp. If you find you are extending the off-cycle, consider whether you actually want to keep running the protocol at all. It may not be earning its place.
The clinical line
Cycle lengths and off-cycle decisions for any specific compound and any specific person are clinical questions that benefit from clinician input where the protocol is non-trivial. The general framework above is research-context, not personalised advice.